Online citations, reference lists, and bibliographies.

Let Food Be Thy Medicine.

R. Minocha
Published 2015 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Author Contributions:Drs Craiglow and King had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: King. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: All authors. Critical revision of the manuscript for important intellectual content: All authors. Study supervision: King.
This paper references
10.1126/scitranslmed.3007811
CXCL10 Is Critical for the Progression and Maintenance of Depigmentation in a Mouse Model of Vitiligo
M. Rashighi (2014)
10.1038/jid.2011.463
A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T cell accumulation in the skin
J. Harris (2012)
10.1111/bjd.12517
Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment
B. Strober (2013)
10.1111/phpp.12100
Oral and systemic photoprotection.
A. C. Chen (2014)
10.1111/j.1365-2133.2012.11168.x
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo‐controlled dose‐ranging study
K. Papp (2012)
10.1001/archderm.1938.01480150063010
Dermatologic symptoms of vitamin deficiencies.
Herman Goodman (1938)
10.1038/jid.2014.260
Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis.
B. Craiglow (2014)
10.1111/bjd.12266
A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
W. Ports (2013)
10.1001/ARCHDERM.1997.03890480045006
Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A.
W. Westerhof (1997)
10.1038/jid.2009.25
Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis.
M. Boy (2009)
10.1016/S0190-9622(89)70144-4
Nutritional deficiency and the skin.
S. Miller (1989)
10.1111/jdv.12081
Tofacitinib (CP‐690,550), an oral Janus kinase inhibitor, improves patient‐reported outcomes in a phase 2b, randomized, double‐blind, placebo‐controlled study in patients with moderate‐to‐severe psoriasis
C. Mamolo (2014)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar